Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2020-07-27 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - "DULOXETINE HYDROCHLORIDE ENTERIC CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 100% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of a drug registration by the National Medical Products Administration of China. It is a short announcement (2182 characters) that informs the market about a regulatory milestone related to a product, not a financial report or detailed filing. There is no financial data, no mention of annual or quarterly results, no voting results, no management changes, and no detailed report attached or referenced. The document is clearly an announcement of a corporate event related to product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-07-27 English
VOLUNTARY ANNOUNCEMENT - "MEMANTINE HYDROCHLORIDE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of a new drug product by a regulatory authority. It does not contain financial data, financial results, or detailed report content. The document is short (2046 characters) and serves as an announcement of a regulatory or business development event rather than a formal report or filing. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance documents or certifications. The best fitting category is a general Regulatory Filing (RNS) as it is a regulatory announcement about product approval without financial data or report content.
2020-07-21 English
VOLUNTARY ANNOUNCEMENT - "ACARBOSE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the drug registration approval of a product called 'Acarbose Tablets'. It is an announcement of a regulatory approval event, not a financial report, management change, or shareholder meeting material. The document is short (2034 characters) and does not contain financial data, earnings, or detailed management discussion. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-07-21 English
2019 CORPORATE SOCIAL RESPONSIBILITY REPORT
Environmental & Social Information Classification · 95% confidence The document is a detailed report prepared by CSPC Pharmaceutical Group Limited covering various aspects of the company's social responsibility, environmental, social, and governance (ESG) practices for the year 2019. It includes sections on social responsibility management, corporate governance structure, stakeholder engagement, environmental protection, employment practices, and charitable activities. The report explicitly states it is prepared in accordance with the Environmental, Social and Governance Reporting Guideline issued by the Hong Kong Stock Exchange and covers the financial year 2019. There is no indication that this is a financial report like an annual or interim report, nor is it an announcement or a certification. The content and structure align with an Environmental & Social Information report, focusing on ESG factors rather than financial performance or governance rules alone. Therefore, the appropriate classification is Environmental & Social Information (SR). The document length and detail confirm it is the report itself, not just an announcement.
2020-07-20 English
VOLUNTARY ANNOUNCEMENT - "CELECOXIB CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited regarding the approval of a drug registration for their product 'Celecoxib Capsules'. It is labeled as a 'Voluntary Announcement' and contains no financial data, no detailed report, or financial statements. The length is only 2321 characters, which is quite short and typical for an announcement rather than a full report. There is no indication that this is a regulatory filing or a report publication announcement. The content focuses on a product approval update, which is a corporate announcement but does not fit into categories like financial reports, management changes, or legal proceedings. Given the options, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-07-14 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, CSPC Pharmaceutical Group Limited, detailing changes in issued share capital and share buybacks. It includes specific data on share issues, repurchases, and confirmations related to compliance with listing rules. The content focuses on reporting changes in share capital and share repurchases, which aligns with announcements regarding share capital changes rather than a full financial report or earnings release. The document is not a full annual or interim report, nor is it a proxy statement or voting result. It is a regulatory disclosure about share capital changes and repurchases, fitting the category of Share Issue/Capital Change (SHA). The document length (8262 characters) and detailed data support it being a substantive disclosure rather than a brief announcement or certification. Therefore, the appropriate classification is SHA with high confidence.
2020-07-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.